Boardroom Alpha
Meeting calendar
CDNA · Annual meeting · Thursday, June 11, 2026

Caredx Inc

5 nominees · 5 ballot items.

Elect five directors; ratify Deloitte & Touche LLP as independent auditor for 2026; advisory (non-binding) approval of named executive officer compensation; advisory (non-binding) vote on the frequency of future say-on-pay votes (Board recommends annual); approve an amendment to the 2024 Equity Incentive Plan to increase the share reserve; and transact any other properly brought business.

Market cap
$2.1B
1Y TSR
+74.7%
Board grade
B-
Record date
Apr 15, 2026
Filing
DEF 14A
Meeting concluded · Jun 11, 2026

Follow how the vote landed and what changed on Caredx Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot5

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Vote to elect five directors (Fred E. Cohen, R. Bryan Riggsbee, Suresh Gunasekaran, Michael D. Goldberg and John W. Hanna) to serve until the 2027 annual meeting or until their successors are elected and qualified.

  2. 2

    Ratification of Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the appointment of Deloitte & Touche LLP as CareDx's independent registered public accounting firm for the fiscal year ending December 31, 2026.

  3. 3

    Advisory Vote on Executive Compensation (Say-on-Pay

    ManagementBoard: FOR

    Non-binding, advisory vote to approve the compensation of the Company's named executive officers as disclosed in the proxy statement.

  4. 4

    Advisory Vote on Frequency of Advisory Votes on Executive Compensation

    ManagementBoard: FOR

    Non-binding, advisory vote to select the preferred frequency (ONE YEAR, TWO YEARS, or THREE YEARS) for future advisory votes on executive compensation; the Board recommends ONE YEAR (annual votes).

  5. 5

    Approval of Amendment to the 2024 Equity Incentive Plan

    ManagementBoard: FOR

    Approve an amendment to the 2024 Equity Incentive Plan to increase the number of shares available for issuance by 1,600,000 shares (and a corresponding increase in ISOs), subject to adjustment under the plan.

Director elections

Nominees on the ballot5

Independent
Tenure on this board
23.5 yrs
Also a director at
Kyverna Therapeutics Inc (KYTX)Intellia Therapeutics Inc (NTLA)
Ownership

Top institutional holders10

Latest 13F quarter
1BAMCO INC /NY/6.5%3,336,409$58M
2STATE STREET CORP5.3%2,760,385$48M
3BlackRock, Inc.4.6%2,359,783$41M
4ARK Investment Management LLC4.3%2,227,556$39M
5DEERFIELD MANAGEMENT COMPANY, L.P.4.2%2,191,000$38M
6BRAIDWELL LP4.2%2,173,146$38M
7VANGUARD CAPITAL MANAGEMENT LLC4.2%2,160,457$38M
8Boston Partners3.6%1,883,534$33M
9GAGNON SECURITIES LLC3.4%1,761,874$31M
10BlackRock, Inc.3.0%1,543,216$27M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Caredx Inc 2026 annual meeting?
Caredx Inc (CDNA) holds its 2026 annual shareholder meeting on Thursday, June 11, 2026.
What is the record date for the Caredx Inc 2026 meeting?
The record date for the Caredx Inc 2026 meeting is Wednesday, April 15, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Caredx Inc's 2026 meeting?
The board is presenting 5 director nominees at the Caredx Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Caredx Inc 2026 meeting?
Shareholders will vote on 5 proposals at the Caredx Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer